PriceTargets.com logo

NASDAQ:RDHL - RedHill Biopharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.50
  • Forecasted Upside: 142.15 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$7.64 As of 01/22/2021 01:00 AM ET
▼ -0.12 (-1.55%)
1 month | 3 months | 12 months
Get New RedHill Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RDHL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RDHL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$18.50
▲ +142.15% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for RedHill Biopharma in the last 3 months. The average price target is $18.50, with a high forecast of $26.00 and a low forecast of $12.00. The average price target represents a 142.15% upside from the last price of $7.64.
Buy
The current consensus among 4 investment analysts is to buy stock in RedHill Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2019
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2019
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2020
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2020Roth CapitalLower Price TargetBuy$16.00 ➝ $12.00High
i
10/13/2020Ascendiant Capital MarketsReiterated RatingBuy$22.00High
i
9/11/2020BTIG ResearchInitiated CoverageBuy$26.00High
i
3/5/2020HC WainwrightReiterated RatingBuy$18.00 ➝ $14.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
2/27/2020Roth CapitalLower Price Target$20.25 ➝ $15.00Medium
i
11/20/2019HC WainwrightReiterated RatingBuy$18.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/4/2019HC WainwrightReiterated RatingBuy$18.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
10/21/2019HC WainwrightSet Price TargetBuy$16.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
7/12/2019WBB SecuritiesUpgradeBuy ➝ Strong-Buy$17.00High
i
7/8/2019Ascendiant Capital MarketsSet Price TargetBuy$23.00Medium
i
Rating by Ed Woo at Ascendiant Capital Markets
3/12/2019WBB SecuritiesUpgradeSpeculative Buy ➝ Buy$17.00High
i
2/27/2019HC WainwrightReiterated RatingReduce ➝ Buy$16.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/14/2019HC WainwrightSet Price TargetBuy$36.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/31/2018WBB SecuritiesInitiated CoverageBuy$5.36Medium
i
12/12/2018LADENBURG THALM/SH SHSet Price TargetBuy$24.00Medium
i
Rating by Matthew Kaplan at LADENBURG THALM/SH SH
11/14/2018HC WainwrightSet Price TargetBuy$36.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
10/23/2018HC WainwrightSet Price TargetBuy$36.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
7/31/2018HC WainwrightReiterated RatingBuyHigh
i
Rating by Swayampakula Ramakanth at HC Wainwright
7/2/2018HC WainwrightReiterated RatingBuy$36.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
6/25/2018LADENBURG THALM/SH SHInitiated CoverageBuy$20.00Low
i
5/9/2018HC WainwrightSet Price TargetBuy$36.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/26/2018Nomura SecuritiesInitiated CoverageBuy$18.00High
i
11/21/2017HC WainwrightReiterated RatingBuy$36.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/14/2017Roth CapitalLower Price TargetBuy$27.00 ➝ $20.00N/A
i
Rating by Scott Henry at Roth Capital
10/6/2017Seaport Global SecuritiesInitiated CoverageBuy ➝ Buy$19.00N/A
i
Rating by V. Bernardino at Seaport Global Securities
10/4/2017Roth CapitalReiterated RatingBuy$27.00Medium
i
Rating by Scott Henry at Roth Capital
10/4/2017HC WainwrightReiterated RatingBuy ➝ Buy$33.00 ➝ $36.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
9/13/2017UBS GroupInitiated CoverageReduceMedium
i
7/31/2017Roth CapitalSet Price TargetBuy$27.00High
i
Rating by Scott Henry at Roth Capital
7/26/2017HC WainwrightSet Price TargetBuy$33.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
6/16/2017(FBRC)Reiterated RatingBuyLow
i
Rating by Vernon Bernardino at (FBRC)
6/15/2017HC WainwrightSet Price TargetBuy$33.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/4/2017Roth CapitalSet Price TargetBuy$26.00Low
i
Rating by Scott Henry at Roth Capital
5/4/2017HC WainwrightSet Price TargetBuy$33.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/5/2017(FBRC)Reiterated RatingBuyLow
i
Rating by Vernon Bernardino at (FBRC)
2/25/2017HC WainwrightSet Price TargetBuy$33.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
2/24/2017(FBRC)Reiterated RatingOutperform ➝ Outperform$36.00 ➝ $25.00N/A
i
Rating by Vernon Bernardino at (FBRC)
12/14/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
11/16/2016(FBRC)Reiterated RatingBuyN/A
i
10/12/2016(FBRC)Reiterated RatingOutperform$36.00N/A
i
Rating by Vernon Bernardino at (FBRC)
10/7/2016HC WainwrightSet Price TargetBuy$33.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
10/6/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
9/9/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
8/25/2016(FBRC)Reiterated RatingOutperform$36.00N/A
i
Rating by Vernon Bernardino at (FBRC)
7/27/2016(FBRC)Boost Price TargetOutperform$33.00 ➝ $36.00N/A
i
Rating by Vernon Bernardino at (FBRC)
5/3/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
4/13/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
3/29/2016Nomura SecuritiesReiterated RatingBuyN/A
i
Rating by Shibani Malhotra at Nomura Securities
3/11/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
3/2/2016Nomura SecuritiesReiterated RatingBuyN/A
i
Rating by Shibani Malhotra at Nomura Securities
2/28/2016HC WainwrightReiterated RatingBuy$33.00N/A
i
2/28/2016(FBRC)Reiterated RatingOutperform$33.00N/A
i
2/27/2016Roth CapitalReiterated RatingBuyN/A
i
Rating by Scott Henry at Roth Capital
2/10/2016Nomura SecuritiesReiterated RatingBuy$25.00N/A
i
(Data available from 1/22/2016 forward)
RedHill Biopharma logo
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Read More

Today's Range

Now: $7.64
$7.58
$7.80

50 Day Range

MA: $8.43
$7.37
$9.83

52 Week Range

Now: $7.64
$3.26
$11.35

Volume

218,330 shs

Average Volume

479,591 shs

Market Capitalization

$285.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Frequently Asked Questions

What sell-side analysts currently cover shares of RedHill Biopharma?

The following Wall Street analysts have issued stock ratings on RedHill Biopharma in the last year: Ascendiant Capital Markets, BTIG Research, HC Wainwright, Roth Capital, and Zacks Investment Research.

What is the current price target for RedHill Biopharma?

4 Wall Street analysts have set twelve-month price targets for RedHill Biopharma in the last year. Their average twelve-month price target is $18.50, suggesting a possible upside of 143.4%. BTIG Research has the highest price target set, predicting RDHL will reach $26.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $12.00 for RedHill Biopharma in the next year.

What is the current consensus analyst rating for RedHill Biopharma?

RedHill Biopharma currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RDHL will outperform the market and that investors should add to their positions of RedHill Biopharma.

What other companies compete with RedHill Biopharma?

Other companies that are similar to RedHill Biopharma include Epizyme, Omeros, Theravance Biopharma, Phathom Pharmaceuticals, Karyopharm Therapeutics, Organogenesis, Athenex, Proteostasis Therapeutics, Akero Therapeutics, Lexicon Pharmaceuticals, Radius Health, Zogenix, ORIC Pharmaceuticals, Humanigen and Dyne Therapeutics.

How do I contact RedHill Biopharma's investor relations team?

RedHill Biopharma's physical mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The biotechnology company's listed phone number is 972-3541-3131 and its investor relations email address is [email protected] The official website for RedHill Biopharma is www.redhillbio.com.